In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2-negative breast cancer, what is the preferred adjuvant chemotherapy regimen for premenopausal women — AC-T or TC?

In premenopausal women with genuinely high-risk HR+/HER2- disease (MonarchE and some NATALEE groups, especially Stage III), I believe there remains a role for dose-dense AC/T as the adjuvant chemotherapy backbone. Data from EBCTCG do portray a 2.5–2.6% 10-year recurrence and 1.6% 10-year breast canc...

Both AC → T (doxorubicin/cyclophosphamide followed by paclitaxel) and TC (docetaxel/cyclophosphamide) are preferred adjuvant chemotherapy regimens for high-risk HR+/HER2-negative breast cancer in premenopausal women, according to the NCCN guidelines, with AC → T most commonly used in the United Stat...

In the current era of adjuvant CDK4/6 inhibitor use for high-risk HR+/HER2−breast cancer, especially in premenopausal women, the preferred adjuvant chemotherapy regimen is generally dose-dense AC-T (adriamycin + cyclophosphamide followed by taxane) over TC (docetaxel + cyclophosphamide), particularl...